Breaking Into the Cannabis Market: Balancing the Profits Against the Risks of Non-Compliance

March 15, 2023 12:00pm

Jonathan Havens
Partner | Cannabis Law Practice Co-Chair
Saul Ewing LLP

Matthew J. McCarthy
Special Counsel
Duane Morris LLP

Christine Roussel, PharmD, BCOP, BCSCP
Senior Executive Director, Pharmacy, Laboratory and Medical Research
Doylestown Hospital, Member of the Pennsylvania Board of Pharmacy and Medical Marijuana Advisory Board

In October 2022, the Biden Administration announced that it would begin pardoning all prior offences of simple possession of marijuana and asked that DEA and FDA begin the administrative process to review how marijuana is scheduled under federal law. DEA has also proposed to more than double the amount of cannabis that can be legally manufactured for research in 2023. The implications of rescheduling marijuana are massive, and may transform the cannabis market into one that is legal at the federal as well as state level. In this session, topics of discussion include:

  • Reviewing DEA and FDA stances on Delta 8 THC
    • Are designer compounds worth the risk of attracting DEA or FDA interest?
  • Drawing on the experiences of pre-existing companies within the hemp and medicinal marijuana industries to set their business up as FDA and DEA compliant
  • Developing business solutions for the inability of state companies to use federal banks and federal tax deductions
  • Understanding how hemp products can and cannot be marketed